Bionano Genomics 4,45USD +3,90USD +708,21%
Seite 1 von 21 Neuester Beitrag: 18.04.23 22:31 | ||||
Eröffnet am: | 16.10.19 19:32 | von: moneywork4. | Anzahl Beiträge: | 524 |
Neuester Beitrag: | 18.04.23 22:31 | von: Napyong | Leser gesamt: | 184.860 |
Forum: | Hot-Stocks | Leser heute: | 8 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | 4 | 19 | 20 | 21 21 > |
What’s Happening: On CNBC’s "Mad Money Lightning Round," Jim Cramer said Bionano Genomics is a good spec, but he actually likes CRISPR Therapeutics.
What Bionano Genomics Does: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space.
https://www.benzinga.com/amp/content/24380684
•The firm has a $14 price target on shares (332% upside based on Thursday's close).
•Analyst Kevin DeGeeter says that his estimate is for Bionano to place 156 Saphyr Systems this year, above the 150 target set by the company.
•Multiple clinical validation studies to support reimbursement are enrolling well and commercial adoption is leading to higher consumable pull-through that should impact 4Q21 and 2022," he writes.
https://seekingalpha.com/amp/news/...ic-mapping-sales-sees-332-upside
Selbst wenn der Umsatz x10 in 2022 sein sollte würde die Aktie um 7$ wert sein (lt. dem Link)
https://seekingalpha.com/article/...lab-than-marketing-saphyr-success
Was meint ihr dazu? Meine haben sich zu einer Leichte im Depo entwickelt, leider.
- Preliminary Q4 revenue expected between $5.8 and $6.2 million; 45%-55% increase over Q4 2020
- Reached installed base of 164 systems: 69% increase over YE 2020
- Achieved or exceeded all stated goals and milestones for the full year 2021
https://ir.bionanogenomics.com/news-releases/...urth-quarter-and-full
Key findings from evaluation of 59 Heme Samples and 10 Controls:
OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH
OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases
OGM Sensitivity: 98.7%
OGM Specificity: 100%
Positive Predictive Value: 100%
Negative Predictive Value: 98%
OGM Accuracy: 99.2%
First-Pass Success Rate: 100%
Limit of Detection (LOD) for aneuploidies, translocations, interstitial deletions and duplications at 400X: 5% variant allele fraction
Key findings from evaluation of 59 Heme Samples and 10 Controls:
•OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH
•OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases
•OGM Sensitivity: 98.7%
•OGM Specificity: 100%
•Positive Predictive Value: 100%
•Negative Predictive Value: 98%
•OGM Accuracy: 99.2%
•First-Pass Success Rate: 100%
•Limit of Detection (LOD) for aneuploidies, translocations, interstitial deletions and duplications at 400X: 5% variant allele fraction
https://finance.yahoo.com/news/...cation-comprehensive-120000033.html
https://finance.yahoo.com/news/...-processing-solution-130000604.html
...The standardization of the technique was necessary to establish precisely how to use OGM on patients to obtain consistently, accurate results.
Other investigators also have been exploring OGM's potential in specific cancers like acute lymphoblastic leukemias and larger groups of cancer types as well.
There already is some movement in places like Europe and Canada to move away from longtime approaches like FISH and move toward OGM. Kolhe hopes the newly published information about how to use OGM for patients will help do the same in this country.
Later this month, the Georgia Cancer Center will be the first to use OGM for patient care in the United States, Kolhe says. While many centers do not have the OGM technology, providers can send their patients' cells to MCG's Georgia Esoteric and Molecular Lab for testing effectively immediately...
https://www.sciencedaily.com/releases/2023/01/...w7mM0GonTy_-L2ebY79Q
https://ir.bionanogenomics.com/news-releases/...er-and-full-year-2022